Search research articles
Contact Us
Filters
Showing results (251-260 of 259) with videos related to
Page
of 26
Sort By:
You have reached the last page of results.
This site can display upto 259 results.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|
June 4, 2026
Clinical Outcomes of Pre-Transplant Cardiac Prehabilitation in the ICU on Impella 5.5
Anek Jena, Aayushi Pareek, Said Bateh, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|
May 21, 2025
Impella 5.5 as Heart Transplant Bridge Facilitated Rehabilitation and Improves Post-Transplant Outcomes: Retrospective Cohort Study
Sadhana Jonna, Gustavo Olaizola, Lekhya Raavi, et al.
Cancer Cell
|
November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
Thomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant
Mathew Thomas, Wei-Sheng Huang, David Wen, et al.
JAMA Internal Medicine
|
April 20, 2026
Fecal Microbiota Transplant and Multidrug-Resistant Organism Decolonization in Gastrointestinal Disease: A Randomized Clinical Trial
Himanshu Narang, Daizee Talukdar, Bipul Kumar, et al.
Journal of Medicinal Chemistry
|
May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Wei-Sheng Huang, Shuangying Liu, Dong Zou, et al.
Journal of Medicinal Chemistry
|
June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant
Wei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Clinical Genitourinary Cancer
|
May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes
Dimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
The New England Journal of Medicine
|
May 26, 2016
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Flora Peyvandi, Pier M Mannucci, Isabella Garagiola, et al.
Page
of 26
Search research articles
Search
Showing results (251-260 of 259) with videos related to
Sort By:
Page
of 26
You have reached the last page of results.
This site can display upto 259 results.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|
June 4, 2026
Clinical Outcomes of Pre-Transplant Cardiac Prehabilitation in the ICU on Impella 5.5
Anek Jena, Aayushi Pareek, Said Bateh, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|
May 21, 2025
Impella 5.5 as Heart Transplant Bridge Facilitated Rehabilitation and Improves Post-Transplant Outcomes: Retrospective Cohort Study
Sadhana Jonna, Gustavo Olaizola, Lekhya Raavi, et al.
Cancer Cell
|
November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
Thomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant
Mathew Thomas, Wei-Sheng Huang, David Wen, et al.
JAMA Internal Medicine
|
April 20, 2026
Fecal Microbiota Transplant and Multidrug-Resistant Organism Decolonization in Gastrointestinal Disease: A Randomized Clinical Trial
Himanshu Narang, Daizee Talukdar, Bipul Kumar, et al.
Journal of Medicinal Chemistry
|
May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Wei-Sheng Huang, Shuangying Liu, Dong Zou, et al.
Journal of Medicinal Chemistry
|
June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant
Wei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.
Clinical Genitourinary Cancer
|
May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes
Dimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
The New England Journal of Medicine
|
May 26, 2016
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Flora Peyvandi, Pier M Mannucci, Isabella Garagiola, et al.
Page
of 26